Inventor · disambiguated record
Michelle Minhua Han
Also filed as: HAN MICHELLE · HAN MICHELLE MINHUA
21 granted patents·13 pending applications·173 citations·filing 2015–2025
95Inventor score
Files withBRISTOL MYERS SQUIBB CO26UNIV TEXAS4FIVE PRIME THERAPEUTICS INC2BOARD OF REGENTS UNIV OF TEXAS SYSTEM1BRISTOL MAYERS SQUIBB COMPANY1
Top patents by PatentIndex Score
34 records- 0198US9228016B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 5, 2016·85 cites·19 claims
- 0297US10501550B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·9 cites·58 claims
- 0397US10465010B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 5, 2019·9 cites·15 claims
- 0497US9745379B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Aug 29, 2017·11 cites·58 claims
- 0594US12312403B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted May 27, 2025·1 cites·17 claims
- 0694US11084881B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Aug 10, 2021·3 cites·19 claims
- 0794US10077306B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 18, 2018·7 cites·22 claims
- 0893US11713313B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2020·Granted Aug 1, 2023·3 cites·12 claims
- 0993US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 1093US10533052B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 14, 2020·4 cites·30 claims
- 1192US10738043B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2018·Granted Aug 11, 2020·6 cites·12 claims
- 1292US10690674B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 23, 2020·5 cites·27 claims
- 1391US10653791B2Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 19, 2020·10 cites·6 claims
- 1491US10125128B2GLS1 inhibitors for treating diseaseBOARD OF REGENTS UNIV OF TEXAS SYSTEM·Filed 2016·Granted Nov 13, 2018·13 cites·21 claims
- 1588US2024158524A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1687US2024209083A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 1786US11591392B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 28, 2023·1 cites·19 claims
- 1884US11408889B2Anti-GITR antibodies for cancer diagnosticsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 1979US2023050665A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2078US2024174749A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2177US11802162B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 31, 2023·0 cites·25 claims
- 2276US12435136B2Antibodies binding to ILT4FIVE PRIME THERAPEUTICS INC·Filed 2022·Granted Oct 7, 2025·0 cites·42 claims
- 2376US2025326841A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 2476US2025115664A1Antibodies against tim3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2574US2024141059A1Antibodies comprising modified heavy constant regionsBRISTOL MAYERS SQUIBB COMPANY·Filed 2023·Application pending·0 cites
- 2671US2022175921A1Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2768US2025197494A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 2864US11401328B2Antibodies binding to ILT4FIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Aug 2, 2022·0 cites·41 claims
- 2962US12129297B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 29, 2024·0 cites·10 claims
- 3061US2021363242A1Methods of treating cancer with antibodies against tim3BRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 3160US2020268901A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 3255US2020299400A1Antibodies comprising modified heavy constant regionsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 3342US11173145B2Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenaseUNIV TEXAS·Filed 2018·Granted Nov 16, 2021·0 cites·27 claims
- 3441US2019135793A1Heterocyclic inhibitors of kdm5 for the treatment of diseaseUNIV TEXAS·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michelle Minhua Han files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →